Harvard Bioscience Subsidiary Data Sciences International Launches Inhalation Exposure System
Harvard Bioscience, Inc.
Jun. 13, 2018
ST. PAUL, Minn. and HOLLISTON, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a subsidiary of Harvard Bioscience, Inc. (Nasdaq:HBIO) launched a new inhalation and exposure system to meet the evolving needs of researchers.
The DSI Buxco Inhalation Exposure System is designed with the ease-of-use desired by new researchers, while providing the performance and flexibility required by experts. Using remote sensors and hardware control systems linked by a microprocessor-based feedback loop, the system enables a high degree of protocol repeatability, translating into high yield exposure studies with a reduced level of manual oversight. DSI’s unique integrated system gives researchers the ability to perform accurate real-time respiration monitoring during exposure using FinePointe software. This is critical for determining accurate deposition levels, while improving animal welfare.
Jeffrey Duchemin, President and CEO of Harvard Bioscience said, “Delivering drugs to the lungs is gaining in popularity for a variety of systemic diseases.” He continued, “Our expertise in respiratory instrumentation technology uniquely positions us in this rapidly growing market."
The U.S. Food & Drug Administration and pharmaceutical companies are placing an increased focus on inhalation as a method for drug administration over the more traditional ingestion method for both respiratory and systemic diseases. The market for these types of drugs is approximately $48 billion.1 With inhalation delivery, less drug is needed to be effective, reducing the risk of side effects.2 DSI’s inhalation exposure system can assist in the development of these drugs as well as numerous other applications including development of animal models and testing of products, biological threats, and environmental pollutants.
About Data Sciences International
Data Sciences International (DSI) provides a complete preclinical platform to assess physiological data for research ranging from basic, to drug discovery, and drug development. DSI is the leading provider of telemetry systems, pulmonary solutions, associated software platforms, and services. DSI is a subsidiary of Harvard Bioscience (Nasdaq:HBIO) a global developer, manufacturer, and marketer of a broad range of specialized products for life science research. For more information, please visit our website at www.datasci.com.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
Contact:Harvard BioscienceCorey ManchesterVice President, Corporate ControllerTel: 508 893 8999
1Pulmatrix Inc. (2016). “Pulmatrix Highlights Recent Report Predicting Rapid Growth for Inhaled Drug Delivery Methods”. https://ir.pulmatrix.com/2016-09-23-Pulmatrix-Highlights-Recent-Report-Predicting-Rapid-Growth-for-Inhaled-Drug-Delivery-Methods
2Moore S. (2017). “Looking to the Future – The Route for Inhaled Medications and Inhalation Technology”. https://www.pharmoutsourcing.com/Featured-Articles/345029-Looking-to-the-Future-The-Route-for-Inhaled-Medications-and-Inhalation-Technology/